INOC – Candiolo National Cancer Institute
INOC – Candiolo National Cancer Institute is a center specializing in the treatment of cancer, a national and international leader in oncology, which opened in 1996 thanks to the efforts of the Allegra Agnelli Foundation for Cancer Research.
Recognized in 2013 as an Institute for Hospitalization and Treatment with Scientific Character (IRCCS), it is a research hospital where clinical and scientific activities proceed together to provide patients with increasingly effective care, based on state-of-the-art procedures and technologies and constant staff upgrading.
It is part of the Piedmont and Aosta Valley Oncology Network since 2008 and is a member of Alliance Against Cancer (ACC) since 2016, and has been a full member of the European Organization of Cancer Institutes (OECI) as a Comprehensive Cancer Center with Research Excellence.
INOC is currently a member of EUNetCCC (European Network of Comprehensive Cancer Centers), a European Joint Action aimed at creating and strengthening a network of Comprehensive Cancer Centers at the European level. It also participated in the European Joint Action CCI4EU ( Comprehensive Cancer Infrastructures for Europe), which concluded in 2025, dedicated to strengthening regional cancer care infrastructure and reducing disparities in access to cancer care.
It receives more than 35,000 patients each year, with personalized pathways in day hospital or inpatient care.
Our mission: research and care
At INOC research inspires treatment, and treatment inspires research.
Every day, we work toward a specific goal: to treat and cure people with cancer in ways that are increasingly effective and personalized, improving their quality of life and offering them new prospects for good health.
Our clinical and scientific activities proceed in synergy to prevent, diagnose, control, and defeat malignancies with increasingly targeted and innovative strategies. At the same time, we are committed to disseminating research advances and training the health and science professionals of today and tomorrow, because shared knowledge is integral to care.
This integration of science and clinical practice is fully realized through participation in national and international clinical trials, which are the bridge between laboratory and patient bedside. As a result of these studies, our patients have access to innovative and promising treatments that are often available years before they become widely available.
Every day at INOC science and care come together to build a future in which cancer can be increasingly prevented, controlled, and defeated.
To support this mission, the Institute has already established an oncology biobank, which collects and stores biological samples donated by patients, making them available to researchers to study the molecular mechanisms of tumors, identify new therapeutic targets, and develop increasingly precise diagnostic tools. The Biobank is now the heart of BioLife, the integrated translational research platform that the Institute is developing to link biological samples and patient data with advanced laboratory models and cutting-edge technologies for studying the molecular characteristics of tumors. Once fully operational, the Biobank will be the largest oncology biobank in Italy—a strategic asset that will help accelerate progress in cancer research and the development of personalized medicine approaches.
A network of collaborations
At INOC research and patient care are advancing thanks in part to a strong network of scientific and academic collaborations.
We operate under an agreement with the University of Turin and the Italian Institute for Genomic Medicine (IIGM), two institutions that share our commitment to innovation and progress in the fight against cancer.
Collaboration with the University of Turin reinforces our dual vocation for research and education. Through this synergy, researchers, physicians and students work side by side in joint projects, fostering the transfer of scientific knowledge into clinical practice and training the next generation of medical and oncology research
The partnership with the Italian Institute for Genomic Medicine (IIGM), on the other hand, allows us to integrate cutting-edge genomic research into the patient care pathway. IIGM’s expertise allows us to translate discoveries about the cancer genome into concrete tools to prevent, diagnose, and treat cancers in increasingly precise and personalized ways.
Thanks in part to these synergies, INOC is now a center of excellence recognized throughout Europe, capable of combining education, basic and applied research, technological innovation, and patient care into an integrated model of translational and personalized medicine.
Certifications
Our commitment to Quality and Safety has led us to pursue and obtain important certifications of excellence in the health care industry.
In May 2022, the Institute was awarded accreditation by Organization of European Cancer Institutes (OECI https://www.oeci.eu)– the network that groups the most important cancer research and treatment centers in Europe – with the designation of “Comprehensive Cancer Center,” the highest award given by OECI.
This certifies that the Institute meets the highest standards, elaborated at the European level, in the field of oncology patient care and treatment and translational clinical cancer research, focusing on patient-centeredness and involvement and multidisciplinary care.
In September 2026, the Institute was redesignated as a Comprehensive Cancer Center with Research Excellence.
The Institute’s Transplant Center (included in the Turin Metropolitan Transplant Center Program) has been accredited as a facility of excellence by the European/US JACIE-FACT system and the National Transplant Center since July 2013.
In April 2026, the Ovarian Cancer Center and the Division of Gynecologic Oncology and Hereditary Cancers at INOC received international ESGO accreditation.
Awarded by the European Society of Gynecological Oncology, ESGO accreditation certifies INOC as a Center of Excellence for advanced ovarian cancer surgery, officially placing it within the elite network of European facilities capable of offering the highest surgical and clinical standards for the treatment of ovarian cancer.
In August 2026, INOC’s Nuclear Medicine Department received the international EARL certification.
This certification, promoted by the European Association of Nuclear Medicine (EANM), certifies that the entire PET/CT diagnostic process — from the measurement of the radioactive tracer to the production of the final images — meets recognized European quality standards.
In 2025, the Institute received 3 Pink Stamps, valid for the two-year period 2026-2027, representing the highest recognition of a “woman-friendly” hospital, awarded by the National Observatory on Women’s Health and Gender, in recognition of the attention and efficiency of services dedicated to the prevention, diagnosis and treatment of women’s diseases.
In 2025, the Institute received 1 Blue Stamp from the Onda ETS Foundation for excellence in services in prevention, diagnosis, treatment, and rehabilitation of prostate cancer, with a focus on post-surgical functional complications.
As of November 2022, the Institute has achieved ISO 45001:2018 certification, aimed at implementing and maintaining an effective and efficient occupational health and safety management system, pursuing continuous performance improvement through the identification and assessment of risks.
Since November 2016, INOC —the Candiolo National Oncology Institute—has adopted a Quality Management System focused on process effectiveness and patient satisfaction, for which it has obtained Quality Certification in accordance with the ISO 9001:2015 standard from the certification body Bureau Veritas.
The panel of experts from Bureau Veritas certified the quality of all organizational processes related to patient care, research, and staff training, highlighting senior management’s commitment, the strong focus on patient care and support, and the excellent quality of basic, translational, and clinical research.
